Multivesicular liposome formulations for the sustained delivery of interferon α-2b

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Acta Pharmacologica Sinica

• Publication date

  2005-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1745-7254.2005.00188.x
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles.

  2005cited by this paper
• Sustained release of cisplatin from multivesicular liposomes: potentiation of antitumor efficacy against S180 murine carcinoma.

  2004cited by this paper
• Modulation of the sustained delivery of myelopoietin (Leridistim) encapsulated in multivesicular liposomes (DepoFoam).

  2003cited by this paper
• The sustained granulopoietic effect of progenipoietin encapsulated in multivesicular liposomes.

  2003cited by this paper
• Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS).

  2003cited by this paper
• Sustained-delivery of an apolipoprotein E-peptidomimetic using multivesicular liposomes lowers serum cholesterol levels.

  2002cited by this paper
• Treatment of hepatitis B

  2002cited by this paper
• Treating cancer with PEG Intron

  2002cited by this paper
• A lipid based depot (DepoFoam technology) for sustained release drug delivery.

  2002cited by this paper
• Sustained-delivery of an apolipoproteinE-peptidomimetic using multivesicular liposomes lowers serum cholesterol levels

  2002cited by this paper
• Liposomes as sustained release system for human interferon-gamma: biopharmaceutical aspects.

  2001cited by this paper
• Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam technology.

  2001cited by this paper
• Pegylated interferon‐α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data

  2000cited by this paper
• Conformational stability of human interferon-gamma on association with and dissociation from liposomes.

  2000cited by this paper
• Safety Assessment of Encapsulated Morphine Delivered Epidurally in a Sustained-Release Multivesicular Liposome Preparation in Dogs

  2000cited by this paper
• Protein Instability in Poly(Lactic-co-Glycolic Acid) Microparticles

  2000cited by this paper
• DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs.

  2000cited by this paper
• Interaction of recombinant interleukin-2 with liposomal bilayers.

  1998cited by this paper
• Multivesicular liposome (DepoFoam) technology for the sustained delivery of insulin-like growth factor-I (IGF-I).

  1998cited by this paper
• Development and Use of Enzyme-Linked Immunosorbent Assays (ELISA) for the Detection of Protein Aggregates in Interferon-Alpha (IFN-α) Formulations

  1997cited by this paper
• Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam.

  1993cited by this paper
• Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study.

  1993cited by this paper
• Preparation of multivesicular liposomes.

  1983cited by this paper

• Pharmacokinetic profile and in vivo anticancer efficacy of anagrelide administered subcutaneously in rodents

  2025cites this paper
• Interferon alpha-2b (IFNα2b) in precision oncology: Innovations in delivery and combinatorial immunotherapy

  2025cites this paper
• Short-term exposure with high-dose interferon-α induces apoptosis in neuroblastoma cells in G0/G1 phase of the cell-cycle.

  2025cites this paper
• Long-acting parenteral formulations of hydrophilic drugs, proteins, and peptide therapeutics: mechanisms, challenges, and therapeutic benefits with a focus on technologies

  2024cites this paper
• Challenges in the development of long acting injectable multivesicular liposomes (DepoFoam® technology).

  2024cites this paper
• Intramuscular injection of palmitic acid-conjugated Exendin-4 loaded multivesicular liposomes for long-acting and improving in-situ stability

  2024cites this paper
• Multichamber PLGA Microparticles with Enhanced Monodispersity and Encapsulation Efficiency Fabricated by a Batch‐Microfluidic Hybrid Approach

  2023cites this paper
• Impact of particle size of multivesicular liposomes on the embolic and therapeutic effects in rabbit VX2 liver tumor

  2023cites this paper
• Ni‐Alginate Hydrogel Microspheres with Sustained Interleukin 2 Release to Boost Cytokine‐Based Cancer Immunotherapy

  2022cites this paper
• Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation

  2021cites this paper
• Multivesicular liposome: A lipid-based drug delivery system for efficient drug delivery.

  2021cites this paper
• Multivesicular liposomes as a potential drug delivery platform for cancer therapy: A systematic review

  2021cites this paper
• Multivesicular Vesicles: Preparation and Applications

  2021cites this paper
• Enhancing the antivirus activity of chimeric canine interferon with ricin subunit B by using nanoparticle formulations

  2020cites this paper
• Probing the mechanism of bupivacaine drug release from multivesicular liposomes.

  2019cites this paper
• PEGylated liposomes for topical vaginal therapy improve delivery of interferon alpha

  2017cites this paper
• Liposome-based therapy: An alternative approach to treat Helicobacter pylori infection in high prevalence communities such as Aklavik, NWT

  2016cites this paper
• Recent developments in protein and peptide parenteral delivery approaches.

  2014cites this paper
• In vivo sustained dermal delivery and pharmacokinetics of interferon alpha in biphasic vesicles after topical application.

  2013cites this paper
• Protamine modified metal ion-protein chelate microparticles for sustained release of interferon.

  2011influential citation
• Encapsulation, pharmacokinetics and tissue distribution of interferon α-2b liposomes after intramuscular injection to rats

  2011cites this paper
• Protein spherulites for sustained release of interferon: preparation, characterization and in vivo evaluation.

  2011cites this paper
• Parenteral Delivery of Peptides and Proteins

  2011cites this paper
• This information is current as Polarization Atopic Dermatitis in NC / Nga Mice via Th 1 Ameliorates γ Therapeutic Levels of IFN-Sustained Exogenous Expression of Yoshinobu

  2010cites this paper
• The Development of Sustained Release Formulation for Pharmaceutical Proteins based on Vesicular Phospholipid Gels

  2010cites this paper
• A morphological screening of protein crystals for interferon delivery by metal ion-chelate technology

  2010cites this paper
• Sustained Exogenous Expression of Therapeutic Levels of IFN-γ Ameliorates Atopic Dermatitis in NC/Nga Mice via Th1 Polarization

  2010cites this paper
• Interferon alpha delivery systems for the treatment of hepatitis C.

  2009cites this paper
• Hydrophilic biodegradable microspheres of interferon-alpha and its pharmacokinetics in mice.

  2008cites this paper
• Establishment of Antihuman IFN-α8-Specific Monoclonal Antibodies and Their Application in the Enzyme-Linked Immunosorbent Assay (ELISA)

  2008cites this paper
• Novel Delivery Systems for Interferons

  2007cites this paper
• Pharmacology of Drugs Formulated with DepoFoam™

  2006cites this paper